OncoDrex is a biotech company developing early screening and diagnostics for cancer. OncoDrex's lead product is a novel blood test for the early detection and screening of colorectal cancer. There is an urgent unmet need to develop a technology that uses blood for the detection of colorectal cancer. VastCon’s lead technology is a novel blood test for early detection and screening of colorectal cancer. This technology is based on the discovery of two biomarkers that are present in high concentrations in the peripheral blood of CRC patients and not healthy subjects. In an initial preclinical study, OncoDrex found that the test was highly sensitive and specific to colorectal cancer. This test has the potential to replace currently existing fecal occult blood test (FOBT) by cost effectiveness, higher sensitivity and reliability for the detection of CRC at an early stage. Due to the unpleasantness of FOBT, the compliance rate is very low. Moreover, FOBT detects the presence of blood in faecal matter, which could be due to several factors apart from CRC introducing unreliability and non-specificity into the picture. OncoDrex's aim is to grow into a multinational company developing diagnostics for cancers of many types.